




Observatoire européen des
drogues et des toxicomanies

TDI Prevalence

Linda Montanari, Bruno Guarita

TDI Meeting – 20-21 September 2017

Lisbon, 21 September 2017



TDI Prevalence

- **Purpose: to provide information on number and characteristics of people in drug treatment**
- **Data collection on clients enter + those who stay in drug treatment during a year and do not generate an annual entry**
- **Same reporting centres that report on TDI**
- **One component of the European treatment monitoring strategy**
- **It is a complementary tool to:**
 - the TDI (it concerns the TDI reporting centres)
 - ST.24, Treatment workbook
 - data collected through the OST (OST estimation and facilities survey)



Objective

1. Estimate the “total number of people in contact with treatment services” (NOT ONLY those entering)
2. Improving the picture of the population with drug problems, even when they are considered as stabilised in treatment
3. Have information on treatment capacity and activity, which can be complemented by other tools and indicators
4. Identify a basic profile of the population in treatment, including those in long term treatment



Process

- **2005: first idea of TDI prevalence project**
- **2006: first Guidelines drafted**
- **2006-2007-2008: pilot data collection (13 countries)**
- **2007: feasibility assessment in all NFPs**
- ***(2008-2012: TDI revision)***
- **2013: revision of Guidelines TDI Prevalence**
- **2014: final guidelines presented to NFPs**
- **2015: FONTE template available**
- **2016: first data collection in 7 countries**
- **2017: inclusion in EDR (page 65)**



Guidelines

- **Voluntary**
- **Same definitions as TDI (+ two for items 7 - 8)**
- **Periodical: every three years next → 2019**
- **8 minimum core items:**
 1. *treatment status*
 2. *treatment centre*
 3. *year of starting treatment*
 4. *age*
 5. *sex*
 6. *primary drug*
 7. *duration in treatment*
 8. *OST*



Treatment status

3 groups identified with the purpose of collecting data:

- A. never previously treated entrants**
- B. previously treated entrants, starting a new drug treatment episode during the reporting year**
- C. clients in continuous treatment, being in treatment on the 1st of January of the reporting year and having started the drug treatment episode in the previous year(s)**



Item list

1. Treatment centre type (*same as TDI*)
2. Year of starting treatment (*same as TDI*)
3. Treatment status (*same as TDI*)
4. Sex (*same as TDI*)
- 5. Age (reference period: first treatment contact during the year or 1 of January)**
6. Primary drug (*same as TDI*)
- 7. Duration in treatment**



Pilot data collections 3 exercises (2006-07-08; data 2005-06-07-08)

	2004	2005	2006	2007
BG (25-55%)	-----	Out, Inp	Out, Inp	Out, Inp
CZ (76-98%)	-----	Out, Inp, LTA	Out, Inp, LTA	Out, Inp, LTA
IE (82%)	-----	-----	-----	Out, Inp (m), LTA, GPs
FR (45-61%)	-----	Out	-----	Out
IT (90-95%)	-----	Out	Out	-----
CY (81-100%)	-----	-----	-----	Out, Inp
LV (50-60%)	Out	Out	Out	Out
HU (100%)	-----		Out, Inp	
MT (82%)	-----	All	-----	-----
NL (95%)	All	All	All	All
AT (71-93%)	-----	-----	Out	Out, Inp
PL (100%)	-----		Inp	
SI (90%)	-----	-----	-----	Out
UK (ENG) (98%)Ap-M	-----	-----	Out, Inp	Out, Inp
Total countries	2	7	9	10



First data collection (2016)

- **Not pilot but on a voluntary basis**
- **Data reported in 2016**
- **Data referring to the year 2015**
- **Countries participating (7):**
Cyprus, France, Finland, Latvia, the Netherlands, Romania, UK (England)



Clients by treatment status


	Never treated	Previously treated	In continuous treatment	Total	Units covered	Units covered in TDI
Cyprus	35%	25%	40%	1304	23	22
France	26%	31%	43%	91868	270	270
Finland	15%	49%	37%	1879	90	90
Latvia	21%	19%	60%	1870	NA	28
Netherlands	20%	14%	66%	32223	220	221
Romania	53%	23%	24%	3996	100	96
UK (England)	16%	28%	56%	246908	1143	1086
Total	19%	28%	54%	100%	1846	1813
Total	66845	98181	191546	380048		



Source: 2016 TDI Prevalence

Countries reporting : Cyprus, France, Finland, Latvia, the Netherlands, Romania, UK (England)

Distribution by primary drug among continuous clients (n. 186 646)



Source: 2016 TDI Prevalence
Countries reporting : Cyprus, France, Finland, Latvia, the Netherlands, Romania, UK (England)

Duration in treatment for clients continuous treatment (n. 186 646)

	Less than 6 months	6 to 12 months	1 to 3 years	3 to 5 years	More than 5 years
Finland	24%	18%	35%	9%	14%
Latvia	1%	4%	96%	0%	0%
Netherlands	9%	13%	27%	11%	40%
Romania	20%	18%	44%	8%	10%
UK (England)	7%	8%	34%	14%	37%
Total	7%	9%	33%	14%	36%



Source: 2016 TDI Prevalence

Countries reporting : Cyprus, France, Finland, Latvia, the Netherlands, Romania, UK (England)

Next steps.....

- **Collect data on the year of treatment 2018 on all clients in treatment during the year (1-1-2018 to 31-12-2018)**
- **Report data to the EMCDDA through the FONTE template in September 2019**

